Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review

BACKGROUND: Despite the use of current standard therapy, the prognosis of patients with unresectable hepatocellular carcinoma (HCC) is poor, with median survival times of 40 mo for intermediate HCC (Barcelona Clinic Liver Cancer [BCLC] stage B) and 6–8 mo for advanced HCC (BCLC stage C). Although pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Faiza, Onwumeh-Okwundu, Jennifer, Yukselen, Zeynep, Endaya Coronel, Maria-Kassandra, Zaidi, Madiha, Guntipalli, Prathima, Garimella, Vamsi, Gudapati, Sravya, Mezidor, Marc Darlene, Andrews, Kim, Mouchli, Mohamad, Shahini, Endrit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Systematic Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603457/
https://www.ncbi.nlm.nih.gov/pubmed/34853653
http://dx.doi.org/10.4251/wjgo.v13.i11.1813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603457/
https://www.ncbi.nlm.nih.gov/pubmed/34853653
http://dx.doi.org/10.4251/wjgo.v13.i11.1813

Ejemplares similares